News and Announcements
Hot Calibration Run of the OncoSil Device
- Published August 18, 2016 4:24PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th August 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully completed a supply chain validation process including the first hot (radioactive) calibration delivery of OncoSil™.
In preparation for the commencement of the Company’s planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (Oncopac-1) and the commercialisation of OncoSil™ subject to attainment of CE Mark, the Company restarted de-novo manufacturing of OncoSil™ microparticles in January 2016. The manufacturing, supply chain validation and delivery to clinical and commercial centres of OncoSil™ product is a key step to commercial sales and the treatment of patients in the OncoPac-1 Study.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
